Silver Book Fact

Anti-platelet therapy stroke risk reduction

Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.

Antithrombotic Trialists' Collaboration. Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients. BMJ. 2002; 324(7329): 71-86. http://www.bmj.com/content/324/7329/71.full

Reference

Title
Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients
Publication
BMJ
Publication Date
2002
Authors
Antithrombotic Trialists' Collaboration
Volume & Issue
Volume 324, Issue 7329
Pages
71-86
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
  • Effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset
    A study of the effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset found an estimated impact on long-term health outcomes of 564 quality-adjusted life-years saved…  
  • 277 medicines are currently in development to treat or prevent heart disease and stroke.  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.